Greenphire Announces New London Office to Facilitate Expansion in Europe
Greenphire
, the leading provider of payment technologies for the clinical trials industry, today announced an expansion into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and isdesigned to support the increasing global demand for Greenphire’s products and services.
The expansion reflects the commercial and operational success Greenphire has enjoyed in the last two years. Both global payment technology platforms for Patient and Investigator payments have seen increased adoption within the life sciences industry and the new office in London will play a critical role in continuing to build on the growth Greenphire has experienced.
Sam Whitaker, Founder and CEO, comments “We are excited to execute on this key part of our 2013 strategic plan. Establishing our presence in Europe allows us to support our Enterprise clients in those areas where they conduct research and development, facilitates stronger support of the many clinical investigators conducting research on behalf of biopharmaceutical companies and provides abase from which we can grow our commercial presence in Europe.”
The new UK office address is: Greenphire, 1 EastPoultry Avenue, London, EC1A 9PT, United Kingdom and the London office number is: +44 (0) 208 150 6470
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
